Multicomponent Test Tops PSA for Clinically Significant Prostate Cancers

— Blood-based biomarker test had similar false-positive rate as PSA, while reducing false negatives

June 22, 2026

• 2 min read

Previous research showed that combining the multicomponent blood-based biomarker Stockholm3 test with an MRI-targeted biopsy approach decreased overdetection of prostate cancers, while still detecting clinically significant cancers.In this analysis, the Stockholm3 test identified more clinically significant prostate cancers, while missing fewer cases, compared with standard PSA screening.These results support the use of the Stockholm3 test in the context of a risk-adapted screening approach, researchers said.

A multicomponent blood-based biomarker test that combines prostate-specific antigen (PSA) with additional plasma protein biomarkers, a polygenic risk score, and clinical variables identified more clinically significant prostate cancers, while missing fewer cases, compared with standard PSA screening, according to a secondary analysis of a randomized trial.